Current technologies are limited in their ability to detect various types of cancer in sufficient quantities for testing, added Davis, explaining that the enhanced sensitivity of ApoStream™ will allow physicians to detect early stages of cancer by a simple blood test.

The ApoStream™ system will undergo regulatory approval in the near future and has the potential to greatly accelerate personalized cancer treatment, Davis explained.


"Our technology can allow doctors to easily obtain multiple samples of a patient's circulating cancer cells over time, which will assist the oncologist in selecting the most effective therapy for the patient and in monitoring the effectiveness of treatment," he said. "Our scientific collaborators, investors and customers are very supportive of this commercialization effort and we expect to accelerate the market roll out of these instruments within the next eighteen months."

Davis also pointed out that more accurate diagnosis and more effective treatment strategies will help reduce the overall economic burden of cancer --- estimated to be at $2 billion annually.

About ApoCell, Inc.

Based in Houston, Texas, ApoCell (www.apocell.com) is a privately-held specialty clinical research company. Founded in 2004, the firm is a leader in molecular biomarker detection and analysis and leverages its expertise in the areas of oncology, diabetes, molecular diagnostics and drug development to measure biomarker signatures in clinical trial subjects. The company's proprietary methods provide early proof of mechanism of action and monitor the effectiveness of various types of drugs by measuring biomarker expression patterns in biopsies, blood and rare cell types. The company's facilities are CLIA-certified and compliant with applicable FDA regulations. Since inception, the company has participated in over 120 Phase I, II, and III clinical cancer drug trials for more than 80 sponsor clients worldwide.



Back to HCB News

More HCB News